证券代码：603231 证券简称：索宝蛋白 公告编号：2024-039 宁波索宝蛋白科技股份有限公司 2024年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所上市公司自律监管指引第3号行业信息披露：第十四 号——食品制造》的相关要求，宁波索宝蛋白科技股份有限公司（以下简称"公 司"）现将 2024 年上半年主要经营数据公告如下： 一、按产品类别分类的主营业务销售情况 | 单位：万元 | | --- | | 项目 | 2024年上半年 | | | --- | --- | --- | | | 金额 | 比例 | | 大豆分离蛋白 | 25,356.46 | 32.95% | | 非转基因大豆油 | 16,758.46 | 21.78% | | 组织化蛋白 | 11,607.27 | 15.09% | | 大豆浓缩蛋白 | 16,058.15 | 20.87% | | 其他产品 | 7,163.15 | 9.31% | | 合计 | 76,943.49 | 100.00% | 二、按销售 ...

证券代码：603231 证券简称：索宝蛋白 公告编号：2024-035 根据经营发展需要，董事会同意公司拟以自有（自筹）资金对外投资不超过 人民币 1,500 万 元 （ 或 等 值 外 币 ） 在 新 加 坡 设 立 全 资 子 公 司 SOLBAR INTERNATIONAL PTE.LTD.（暂定名，具体名称以最终核准名称为准），主营业务： 现有及延伸产品的贸易和进出口。并同意拟以自有（自筹）资金对外投资不超过 人民币 2,500 万元（或等值外币）在德国通过全资子公司 SOLBAR INTERNATIONAL PTE.LTD.（暂定名，具体名称以最终核准名称为准）设立全资孙公司 Solbar Germany GmbH（暂定名，具体名称以最终核准名称为准），主营业务：现有及延 伸产品的贸易和进出口。 公司董事会授权董事长及其指定人士负责本次对外投资设立全资子公司及 孙公司的相关工作，包括但不限于后续相关的 ODI 备案及审批手续、签署投资协 议等相关的法律性文件。 本次设立境外全资子公司及孙公司尚需获得政府相关部门的审批许可，以及 根据当地法律可能存在的特别要求或临时性变化而变化，存在未获批准而无法成 ...

A 股每股现金红利 0.50 元 相关日期 证券代码：603231 证券简称：索宝蛋白 公告编号：2024-034 宁波索宝蛋白科技股份有限公司 2023 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2024/6/27 | － | 2024/6/28 | 2024/6/28 | 差异化分红送转： 否 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2024 年 5 月 13 日的 2023 年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 191,459,105 股为基数，每股派发现金红利 0.50 元 ...

东吴证券股份有限公司 关于宁波索宝蛋白科技股份有限公司 首次公开发行网下配售限售股上市流通的核查意见 东吴证券股份有限公司（以下简称"东吴证券"或"保荐机构"）作为宁波索宝 蛋白科技股份有限公司（以下简称"索宝蛋白"或"公司"）首次公开发行股票并在 上海证券交易所主板上市的保荐机构和持续督导机构，根据《证券发行上市保荐 业务管理办法》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监 管要求》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指 引第 11 号—持续督导》《上海证券交易所上市公司自律监管指引第 1 号—规范运 作》等法律法规和规范性文件的要求，对索宝蛋白首次公开发行网下配售限售股 上市流通事项进行了核查，并出具核查意见如下： 本次上市流通的限售股均为公司首次公开发行网下配售限售股。根据公司 《首次公开发行股票主板上市公告书》，本次网下发行采用比例限售方式，网下 投资者应当承诺其获配股票数量的 10%（向上取整计算）限售期限为自公司首次 公开发行并上市之日起 6 个月。即每个配售对象获配的股票中，90%的股份无限 售期，自本次发行股票在上海证券交易所上市交易之日起即可流通； ...

证券代码：603231 证券简称：索宝蛋白 公告编号：2024-033 宁波索宝蛋白科技股份有限公司 关于首次公开发行网下配售限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次限售股上市类型 根据中国证券监督管理委员会出具的《关于同意宁波索宝蛋白科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2023]1851 号），同意宁波索宝 蛋白科技股份有限公司（以下简称"公司"）首次公开发行股票的注册申请并经 上海证券交易所同意，公司获准首次向社会公众公开发行人民币普通股（A 股）股 票 4,786.48 万股，并于 2023 年 12 月 15 日在上海证券交易所挂牌上市。 公司首次公开发行 A 股股票前总股本为 14,359.4305 万股，首次公开发行 A 股股票后总股本为 19,145.9105 万股，其中有限售条件流通股 14,455.3607 万股， 占公司总股本的 75.50%，无限售条件流通股 4,690.5498 万股，占公司总股本的 24.50%。 本次解除限 ...

Group 1: Company Overview and Strategy - Ningbo Suobao Protein Technology Co., Ltd. focuses on the production and sales of non-GMO soybean protein products, adapting to market trends and customer needs [1] - The company aims to enhance R&D and production capacity to meet increasing demand and expand its operational scale [1][3] - The company is strategically positioned to leverage domestic and international market opportunities, emphasizing a dual circulation market strategy [1][4] Group 2: Recent Acquisitions and Investments - The company announced the acquisition of 100% equity in Jilin Houde Storage Logistics Co., Ltd. to support its production needs, with an investment of 220 million yuan for a new processing line with an annual capacity of 200,000 tons [2][3] - The acquisition aims to address the insufficiency of low-temperature soybean meal and oil production capacity [2][5] Group 3: Market Position and Competition - The domestic soybean protein processing industry has around 20 major producers with an annual capacity of approximately 800,000 tons, with the top manufacturers holding about 60% of the market share [4] - The company accounts for approximately 10% of the domestic soybean protein sales volume, indicating a significant market presence [4] Group 4: Financial Performance and Projections - The expected sales amount to related parties for 2024 is projected at 13 million yuan, a decrease from the previous year's estimate of 60 million yuan, attributed to weakened market demand and fluctuating shipping costs [2] - The company emphasizes continuous innovation and market expansion to ensure steady growth and value creation for shareholders [3][5] Group 5: Industry Barriers and Challenges - The soybean protein industry faces several barriers to entry, including market access, brand recognition, technological expertise, and scale advantages [5] - Regulatory standards and quality control measures are becoming increasingly stringent, raising the entry threshold for new competitors [5]

Group 1: Company Overview and Strategy - Ningbo Suobao Protein Technology Co., Ltd. focuses on the production and sales of non-GMO soybean protein products, adapting to market trends and customer needs [1] - The company aims to enhance R&D and production capacity to meet increasing demand and expand its operational scale [1][3] - The company is strategically positioned to leverage opportunities in the "dual circulation" market, emphasizing market-oriented approaches [2][4] Group 2: Recent Acquisitions and Investments - The company announced the acquisition of 100% equity in Jilin Houde Storage Logistics Co., Ltd. to address internal demand for low-temperature soybean meal and enhance production capacity [2][3] - An investment of CNY 220 million is planned for a new soybean processing line with an annual capacity of 200,000 tons [1][2] Group 3: Market Position and Competition - The domestic soybean protein processing industry has around 20 major producers with an annual capacity of approximately 800,000 tons, with the top manufacturers holding about 60% of the market share [4][5] - The company accounts for about 10% of the domestic soybean protein sales volume, indicating a significant market presence [4] Group 4: Financial Performance and Projections - The expected sales to related parties for 2024 are projected at CNY 13 million, a decrease from CNY 60 million in 2023, attributed to weakened market demand and fluctuating shipping costs [2] - The company emphasizes continuous growth through innovation and market expansion to enhance shareholder value [3][5] Group 5: Industry Barriers and Challenges - The soybean protein industry faces several barriers to entry, including regulatory standards, brand recognition, technological expertise, and economies of scale [5] - The increasing quality control standards and regulatory scrutiny in the food industry raise the entry threshold for new competitors [5]

重要内容提示： 一、说明会类型 宁波索宝蛋白科技股份有限公司（以下简称"公司"）已分别于 2024 年 4 月 20 日、4 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了《2023 年 年度报告》及《2023 年年度报告摘要》、《2024 年第一季度报告》。为便于广 会议召开时间：2024 年 5 月 13 日（星期一）16:30-17:30 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 2024 年 5 月 13 日 前 访 问 网 址 https://eseb.cn/1ej11M1T4fS 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司定于 2024 年 5 月 13 日（星期一）16:30-17:30 在"价值在线"（www.ir-online.cn）以网 络互动方式召开宁波索宝蛋白科技股份有限公司 2023 年度暨 2024 年第一季度 业绩说明会，与 ...

证券代码：603231 证券简称：索宝蛋白 宁波索宝蛋白科技股份有限公司 2023 年年度股东大会 会议资料 2024 年 5 月 13 日 1 | 2023 | 年年度股东大会会议须知 3 | 2023 | 年年度股东大会会议议程 5 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 议案一：关于 | 2023 | 年度董事会工作报告的议案 7 | 议案二：关于 | 2023 | 年度监事会工作报告的议案 122 | | | | 议案三：关于 | 2023 | 年度独立董事述职报告的议案 166 | 议案四：关于 | 2023 | 年度财务决算报告的议案 17 | | | | 议案五：关于 | 2023 | 年年度报告及其摘要的议案 20 | 议案六：关于 | 2023 | 年度利润分配方案的议案 21 | | | | 议案七：关于 | 2024 | 年度向金融机构申请综合授信额度的议案 22 | 议案八：关于确认董事 | 2023 | 年度薪酬及 | 2024 | 年度薪酬方案的议案 23 | | 议案九：关于确认监事 | 2023 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 392,657,748.16, representing a decrease of 4.55% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 37,265,469.75, an increase of 47.77% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 33,185,571.63, up by 32.04% compared to the previous year[4] - Basic and diluted earnings per share were both CNY 0.19, reflecting a growth of 5.56%[4] - Total operating revenue for Q1 2024 was ¥392,657,748.16, a decrease of 4.3% compared to ¥411,395,508.19 in Q1 2023[16] - Net profit for Q1 2024 reached ¥37,265,469.75, an increase of 47.7% compared to ¥25,218,829.04 in Q1 2023[17] - Earnings per share for Q1 2024 were ¥0.19, up from ¥0.18 in Q1 2023[18] Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 18,553,120.73, a significant increase of 374.75% year-on-year[4] - Cash inflow from operating activities was ¥466,986,543.15 in Q1 2024, slightly up from ¥466,046,743.70 in Q1 2023[19] - The net cash flow from operating activities for Q1 2024 was $18,553,120.73, a significant increase from $3,907,958.79 in Q1 2023, reflecting improved operational efficiency[20] - The total cash and cash equivalents at the end of Q1 2024 amounted to $350,784,464.51, down from $1,073,142,131.62 at the beginning of the quarter, indicating a significant decrease in liquidity[21] - The total operating cash outflow was $448,433,422.42, slightly lower than $462,138,784.91 in Q1 2023, indicating stable operational costs[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,129,297,349.55, a decrease of 0.52% from the end of the previous year[4] - The company's current assets totaled ¥1,468,641,866.02, down from ¥1,488,723,140.98, indicating a decrease of about 1.73%[13] - Total liabilities decreased to ¥202,687,604.40 in Q1 2024 from ¥251,122,161.42 in Q1 2023, a reduction of 19.2%[16] - The total liabilities decreased from ¥1,488,723,140.98 to ¥1,468,641,866.02, a decline of about 1.35%[13] - The company reported a total of ¥567,954,580.64 in fixed assets, down from ¥574,737,962.16, indicating a decrease of about 1.2%[13] Operational Efficiency - The increase in net profit was primarily attributed to the appreciation of the US dollar, increased interest income, recovery of previously provided bad debts, and a decrease in the cost of major raw materials[7] - Research and development expenses decreased to ¥1,329,836.11 in Q1 2024 from ¥2,895,576.83 in Q1 2023, a decline of 54.0%[16] - Financial expenses showed a significant improvement, with a net income of ¥5,041,406.07 in Q1 2024 compared to a loss of ¥3,768,596.69 in Q1 2023[16] Other Financial Activities - The company reported a non-recurring loss from the disposal of non-current assets amounting to CNY 1,780,922.67[6] - The company recognized government subsidies of CNY 2,422,239.21 that are closely related to its normal business operations[6] - The company paid $10,066,146.69 in taxes during the quarter, which is a significant increase from $5,642,780.22 in the same period last year, reflecting higher taxable income[20] - The cash paid to employees was $31,313,991.78, a decrease from $32,543,360.76 in Q1 2023, suggesting potential cost-cutting measures in personnel expenses[20] - The company experienced a foreign exchange impact of $2,378,100.48 on cash and cash equivalents, contrasting with a negative impact of -$2,402,188.83 in the previous year[21]